PL422526A1 - N-substituted compounds of tacrine, method for producing and application of those compounds - Google Patents

N-substituted compounds of tacrine, method for producing and application of those compounds

Info

Publication number
PL422526A1
PL422526A1 PL422526A PL42252617A PL422526A1 PL 422526 A1 PL422526 A1 PL 422526A1 PL 422526 A PL422526 A PL 422526A PL 42252617 A PL42252617 A PL 42252617A PL 422526 A1 PL422526 A1 PL 422526A1
Authority
PL
Poland
Prior art keywords
application
carbon atom
compounds
tacrine
acridine
Prior art date
Application number
PL422526A
Other languages
Polish (pl)
Other versions
PL235351B1 (en
Inventor
Paweł Szymański
Elżbieta Mikiciuk-Olasik
Ireneusz Majsterek
Nina Chufarova
Kamila Czarnecka
Robert Skibiński
Original Assignee
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL422526A priority Critical patent/PL235351B1/en
Publication of PL422526A1 publication Critical patent/PL422526A1/en
Publication of PL235351B1 publication Critical patent/PL235351B1/en

Links

Abstract

Przedmiotem zgłoszenia jest N-podstawiony związek takryny o wzorze 1, w którym R1, R2, R3, R4 są niezależne wybrane z grupy obejmującej atom wodoru, atom fluorowca, grupę nitrową, grupę aminową, grupę metylową, grupę metoksylową, grupę hydroksylową, grupę trifluorometylową, A oznacza dwuwartościowy fragment alkilenowy, ewentualnie rozgałęziony, mający od dwóch do dwunastu atomów węgla, przy czym łańcuch główny fragmentu alkilenowego A zawiera co najmniej dwa atomy węgla, B oznacza akrydynę, przy czym linia poprowadzona pomiędzy atomem węgla ugrupowania karboksamidowego a podstawnikiem B oznacza wiązanie pojedyncze łączące niewęzłowy atom węgla akrydyny z atomem węgla grupy karbonylowej; albo jego hydrat, solwat lub farmakologicznie dopuszczalna sól. Zgłoszenie dotyczy także wytwarzania przedmiotowego związku i kwasu akrydynokarboksylowego, a także stosowania związków o wzorze 1, w terapii do leczenia choroby nowotworowej ze współistniejącą chorobą Alzheimera.The subject of the application is an N-substituted tacrine compound of formula 1 in which R1, R2, R3, R4 are independently selected from the group consisting of hydrogen, halogen, nitro, amino, methyl, methoxy, hydroxyl, trifluoromethyl , A is a divalent alkylene fragment, optionally branched, having from two to twelve carbon atoms, where the main chain of the alkylene fragment A contains at least two carbon atoms, B is acridine, the line drawn between the carbon atom of the carboxamide moiety and the substituent B is a bond single connecting a non-node acridine carbon atom to a carbonyl group carbon atom; or a hydrate, solvate or pharmacologically acceptable salt thereof. The application also relates to the preparation of the subject compound and acridinecarboxylic acid, as well as the use of compounds of formula 1 in therapy for the treatment of cancer with co-morbid Alzheimer's disease.

PL422526A 2017-08-09 2017-08-09 N-substituted compounds of tacrine, method for producing and application of those compounds PL235351B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL422526A PL235351B1 (en) 2017-08-09 2017-08-09 N-substituted compounds of tacrine, method for producing and application of those compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422526A PL235351B1 (en) 2017-08-09 2017-08-09 N-substituted compounds of tacrine, method for producing and application of those compounds

Publications (2)

Publication Number Publication Date
PL422526A1 true PL422526A1 (en) 2019-02-11
PL235351B1 PL235351B1 (en) 2020-06-29

Family

ID=65270289

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422526A PL235351B1 (en) 2017-08-09 2017-08-09 N-substituted compounds of tacrine, method for producing and application of those compounds

Country Status (1)

Country Link
PL (1) PL235351B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
WO2004032929A2 (en) * 2002-10-09 2004-04-22 Neuropharma, S.A. Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease
WO2014180984A1 (en) * 2013-05-09 2014-11-13 Ikerchem, S.L. Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
WO2004032929A2 (en) * 2002-10-09 2004-04-22 Neuropharma, S.A. Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease
WO2014180984A1 (en) * 2013-05-09 2014-11-13 Ikerchem, S.L. Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings

Also Published As

Publication number Publication date
PL235351B1 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
DK1539700T3 (en) 8-hydroxy quinoline derivatives
BRPI0606319A2 (en) pharmaceutical compounds
DK1678166T3 (en) protein kinase inhibitors
EA200501585A1 (en) DERIVATIVES OF AZETIDINCARBOXAMIDE AND THEIR APPLICATION IN THE TREATMENT OF DISORDERS MEDIATED BY SV1 RECEPTORS
TW200833675A (en) Nicotinamide derivatives
DE602005016261D1 (en) SUBSTITUTED ARYLAMINE DERIVATIVES AND METHOD OF USE
MX2017010230A (en) Substituted mono- and polyazanaphthalene derivatives and their use.
ATE457988T1 (en) A2A ADENOSINE RECEPTOR ANTAGONISTS
CY1107974T1 (en) KINOLIN AND KINAZOLIN DERIVATIVES RELATED TO 5HT1 RECEPTORS
NO20080955L (en) Quinoline derivatives as antibacterial agents
MX2012004848A (en) Tricyclic heterocyclic compounds.
JOP20190239A1 (en) Vmat2 inhibitor compounds and compositions thereof
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
AR054890A1 (en) DERIVATIVES OF QUINOLINA AS ANTIBACTERIAL AGENTS
ATE307810T1 (en) IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS
MX2010006230A (en) Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists.
TW200716547A (en) Piperidin-4-yl-amide derivatives
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
RU2011133128A (en) ANTITUMOR COMPOUNDS DIHYDROPIRAN-2-ONA
RU2011112684A (en) AGENT FACILITATING HAIR GROWTH CONTAINING AN ACTIVE INGREDIENT Derivative 15,15-DIFFOROPROSTAGLANDINE F2α
JO2413B1 (en) Benzoxazine Derivatives And Uses Thereof
MX2020008816A (en) Triazine derivatives for treating diseases relating to neurotrophins.
DE602007001463D1 (en) PYRIMIDINE, CHINAZOLIN, PTERIDINE AND TRIAZINE DERIVATIVES
MX2022014192A (en) Methods of treating prostate cancer.
FR2942625B1 (en) INDOLIC DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES